A phase I study of SU006668 [SU6668] via twice daily oral administration under fed conditions in patients with advanced malignancies.

Trial Profile

A phase I study of SU006668 [SU6668] via twice daily oral administration under fed conditions in patients with advanced malignancies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2011

At a glance

  • Drugs Orantinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top